Tag: Daniel Tassé

Viaskin Peanut

FDA Issues Partial Hold on DBV Viaskin Peanut Patch Trial

Another delay for the long-awaited therapy.
Viaskin Patch

DBV Begins Phase 3 Study of Redesigned Viaskin Peanut Patch in...

Viaskin is testing a new version of their patch designed to address the FDA's concerns.
Viaskin Patch

DBV Announces Positive Topline Results from Phase 3 Trial of Viaskin...

Viaskin Peanut demonstrated a statistically significant treatment effect with 67.0% of subjects meeting the treatment responder criteria after 12 months.
Viaskin Patch

Viaskin Peanut Patch Therapy Delayed Further as DBV Readies Another Phase...

The patch therapy remains in regulatory limbo.
Viaskin Peanut

FDA Wants More Viaskin Peanut Data Resulting in Further Approval Delays

Delays mount pushing trials of modified patch.
DBV Patch Closeup

DBV, Developers of Patch Therapies for Allergies to Peanuts, Milk and...

The company announced they would be laying off 200 employees in Q1.
Viaskin Peanut

FDA Denies Approval of Viaskin Peanut “Patch” Therapy

The FDA raised concerns that adhesion of the patch would affect the efficacy of the therapy.
Viaskin Patch

Will the Viaskin “Patch” Therapy for Peanut Allergy be Approved Soon?...

Company is restructuring in anticipation of delays.
Viaskin-Patch-Delay

FDA Has Questions About Viaskin Peanut Efficacy, Delays Meeting with DBV...

The company warned the FDA's target date for their decision on approval could be delayed.
Viaskin-Patch

FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment...

Next step in the approval process for the therapy scheduled for May 15, 2020.